

Padagis Naloxone⁺

KEY CONSIDERATIONS



TIMELY ACCESS AND ADMINISTRATION OF PADAGIS[®] NALOXONE NASAL SPRAY

In an opioid emergency, brain damage can begin within 4 minutes of breathing cessation, with death potentially following in another 4 to 6 minutes. Quick access and administration of Padagis[®] Naloxone Nasal Spray is crucial in these critical moments.

OSHA RECOMMENDATIONS

While OSHA doesn't currently mandate stocking this drug, they recommend that employers regularly evaluate the specific requirements of their workplace and adjust the first aid kit as needed. Additionally, 48 states have passed Good Samaritan laws.

REPORTING USE OF PADAGIS[®] NALOXONE NASAL SPRAY

Non-prescription medications are not required to be logged by OSHA and are classified as first aid. However, it may need to be recorded if administered alongside other factors for documenting injuries or illnesses, such as when a worker loses consciousness.

POSSIBLE SIDE EFFECTS

Some individuals may experience symptoms like shaking, sweating, nausea, or irritability upon waking after using this product. These effects are normal and to be expected.

STORAGE OF PADAGIS[®] NALOXONE NASAL SPRAY

Store at room temperature or refrigerated, between 36°F and 77°F (2°C to 25°C). Do not freeze. Keep away from excessive heat above 104°F (40°C) and protect from light. Be sure to follow the expiration date printed on the packaging.

FOR OPIOID EMERGENCIES, CALL 911

For questions on Padagis[®] Naloxone Nasal Spray, call 1-866-506-1289

Padagis
Naloxone⁺ is a trademark of Padagis US LLC.
Padagis is a registered trademark of Padagis US LLC